From: Gout. Novel therapies for treatment of gout and hyperuricemia
Total ambulatory visits, and visits to primary care versus specialists | |
Total number of ambulatory care visits | 973 million |
Number of visits for gout | 3.9 million (0.4% of total) |
Percentage of total visits for gout to: | |
Primary care | 69% |
Cardiologists | 10% |
'Other specialists or unknown' | <16% |
Rheumatologists | <2% |
Number of gout patient-specific anti-inflammatory prescriptions (absolute number of prescriptions/year) | |
Colchicine | ~381,000 |
NSAIDs | ~700,000 |
Prednisone | ~341,000 |
Number of gout patient-specific urate-lowering prescriptions (absolute number of prescriptions/year) | |
Allopurinol | 2.8 million |
Probenecid | 8,000 |
Demographics of allopurinol prescribing: percentage of gout patients that are: | |
Caucasian | 80% |
African Americans | 49% |
Asians | 19% |